HRSA released the results of its first two drugmaker audits of 2025 this month.

HRSA Audits Find Two Drugmakers Overcharged for 340B Drugs, Driving Calls for More Drug Industry Oversight

April 29, 2025 Bella Czajkowski, National Correspondent Views

Recent Health Resources and Services Administration (HRSA) audits found that two drugmakers overcharged covered entities for their 340B drugs, fueling [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

HRSA Audits Find Two Drugmakers Overcharged for 340B Drugs, Driving Calls for More Drug Industry Oversight

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski

HRSA Audits Find Two Drugmakers Overcharged for 340B Drugs, Driving Calls for More Drug Industry Oversight

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski

Site Footer Live